Drug Profile
Research programme: cancer therapeutics - Bayer HealthCare/National University of Singapore
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Bayer Schering Pharma; National University of Singapore
- Developer Bayer HealthCare Pharmaceuticals; National University of Singapore
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Singapore
- 01 Mar 2011 Bayer Schering Pharma is now called Bayer Healthcare Pharmaceuticals
- 30 Sep 2008 Preclinical trials in Cancer in Singapore (unspecified route)